NCT02636270View on ClinicalTrials.gov

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 21, 2015

Primary Completion Date

October 14, 2022

Study Completion Date

December 1, 2022

Conditions
Short Stature
Interventions
DRUG

Increlex

Treat PAPP-A2 deficient patients with Increlex

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02636270 - IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency | Biotech Hunter | Biotech Hunter